Remote Electric Neuromodulation Provides Effective Acute Treatment in People With Chronic Migraine 

10/19/2021

As published in Pain Reports, a acute treatment with a remote electric neuromodulation (REN) device (Nerivio; Theranica, Netanya, Israel) provided sustained pain relief in people with chronic migraine.

In a prospective multicenter open-label trial (NCT04194008), 99 participants with chronic migraine demonstrated favorable efficacy of REN, with nearly 60% of participants had pain relief at 2 hours after treatment. Nearly 65% of those participants sustained pain relief at 24 hours posttreatment. Over 20% of participants experienced pain freedom at 2 hours posttreatment. 

"Chronic migraine is characterized by headaches experienced on at least 15 days per month," said Brian Grosberg, MD, director of the Hartford Healthcare Headache Center, who served as the primary investigator of the study. "People with chronic migraine not only have a higher frequency of migraine attacks, but their attacks tend to be more severe than episodic migraine patients. They typically need to take more medications, usually cocktails of preventive and acute medications. The challenge is to relieve the migraine symptoms while avoiding the risk of medication overuse headache (MOH) and other complications. Nonpharmacologic interventions such as REN help meet this need by providing a drug-free treatment option. As a clinically validated, nonpharmacologic acute treatment option for people with migraine, Nerivio is an excellent fit for fulfilling this need."

"To the best of our knowledge, this was the largest clinical trial of acute treatment of migraine specifically targeting chronic migraine patients," said Liron Rabany, PhD, chief Scientist of Theranica and a coauthor of the study paper. "We are determined to continue our clinical development, adding ever-increasing solid evidence of the clinical benefit that REN brings to different subpopulations of people with migraine. All people with migraine, adults or adolescents, should have the option of discussing a nonpharmacologic therapy with their healthcare providers, as a first-line treatment option, or as an adjunct."

The device is worn on the upper arm at the onset of a migraine attack and controlled by an app on the individual's smartphone, allowing patients to set the intensity of their treatment.

Only 1 of the 99 participants reported a mild, local device-related adverse reaction which was resolved independently shortly after the treatment.

Register

We're glad to see you're enjoying PracticalNeurology…
but how about a more personalized experience?

Register for free